ArticleBMJ open respiratory research2025
Impact of dynapenia, presarcopenia and sarcopenia in chronic obstructive pulmonary disease: a prospective cohort study.
Article in BMJ open respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development of an opportunistic chest CT-based nomogram for identifying low muscle mass in hospitalized patients with COPD.Frontiers in medicine · 2026Article
- Association between quantitative CT-derived body composition and lung low-attenuation area percentage: discrimination of high LAA% burden.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundReduced muscle strength and decreased muscle mass (sarcopenia) are known predictors of poor prognosis in chronic obstructive pulmonary disease (COPD). Isolated muscle weakness (dynapenia) or low muscle mass alone (presarcopenia) may also negatively impact outcomes. This study aims to compare the prognostic significance of dynapenia, presarcopenia and sarcopenia.
methodsThis prospective study enrolled patients with spirometry-confirmed COPD at a tertiary medical centre. Participants were categorised into dynapenia, presarcopenia and sarcopenia based on the presence of reduced handgrip strength (<28 kg for men, <18 kg for women) and/or decreased muscle mass (<7.0 kg/m
resultsA total of 494 patients were enrolled, comprising 211, 59, 111 and 113 patients in the control, presarcopenia, dynapenia and sarcopenia groups, respectively. Both dynapenia and sarcopenia groups had shorter 6 min walk distances and more SPPB score ≤9 than the control group (348.7 m and 304.4 m vs 420 m, p<0.001; 30% and 44% vs 11%, p=0.036). Patients with presarcopenia and sarcopenia were prone to severe exercise-induced desaturation than the dynapenia and control group (26% and 30% vs 9% and 18%, p=0.001). The 2-year mortality was similar in the control, presarcopenia and dynapenia groups but considerably less than that in the sarcopenia group (6.2% vs 10.2% vs. 9.0% vs. 25.7%, p<0.05). Univariate and multivariate analysis showed that only sarcopenia was associated with an increased risk of mortality (HR: 4.93, 95% CI 2.56 to 9.50, p<0.001; HR: 2.07, 95% CI 1.02 to 4.21, p<0.05).
conclusionsAside from sarcopenia, both presarcopenia and dynapenia are not associated with an increased risk of mortality in COPD. However, patients with dynapenia experience significant functional deterioration, while those with presarcopenia present with more severe exercise-induced desaturation. Identifying each phenotype is crucial for the holistic management of COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.